Rhythm Pharmaceuticals Inc RYTM

$89.82 -0.96 (-1.06%)

Valuation

Market cap
6,221,425,000
Revenue TTM
$189,760,000
Net income TTM
$-196,540,000
PE ratio
0.00
Forward PE
—
Profit margin
-103.57%
Debt to equity
0.00

Trading

Volume
543,800
Avg volume
694,366
Day's range
$89.49 – $91.42
Shares out
68,533,000
Stochastic %K
27%
Beta
2.01
Analysts
Strong Sell
Price target
$140.00

Price

Company profile

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alst...

Show more

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
857 264 4280
Website
https://rhythmtx.com
Address
222 Berkeley Street, 12th Floor, Boston, United States

Latest news

Stocktwits

Stonky_Mcprofitface Oct 12, 7:48 PM
$RYTM Fill my order. I’m not coming back tomorrow.
0 replies
Quantumup Oct 12, 6:42 PM
H.C. Wainwright⬆️ $RYTM's PT to $130 from $105/reit'd Buy after +'g Japanese HO sales2its mkt model/revising near/medium-term operating expense ests $LLY $NVO VKTX GPCR PTN HCW said -- IMCIVREE, a melanocortin-4 receptor (MC4R) agonist which received orphan drug designation by the MHLW in March 2025, is the first therapy approved in Japan to treat acquired HO. Rhythm currently expects to launch IMCIVREE before the end of 2026, pending final pricing determination. Rhythm estimates there are 5,000 to 8,000 people living with acquired HO in Japan. We anticipate that the company should be able to launch the drug in a timely manner before the end of this year and expect list pricing to be disclosed in the coming months, probably at a level between U.S. and European pricing. As a reminder, the Japanese market may initially exhibit gradual uptake due to the requirement for prescriptions to be renewed fortnightly for newly launched drugs, but we expect sales to ramp steadily starting next year.
0 replies
Stonky_Mcprofitface Oct 9, 12:04 PM
$RYTM This is a selloff similar to the last one to the $80S but it also represents a buying opportunity as HO and soon Japan and Canada will propel additional sales. Only risk is data from biv.
0 replies
abcdzepeda Oct 7, 11:04 PM
$RYTM  can anyone refresh my memory on when we have an upcoming catalyst that would perhaps help drive the stock Price back up? 
0 replies
Hognose Oct 6, 11:09 PM
$RYTM chart looks terrible. Bad action every pop gets sold.
0 replies
Freakyguy666 Oct 5, 1:28 AM
$RYTM $VKTX you don’t understand shit bro. Sit down.
1 replies
GPTInsights Oct 5, 1:18 AM
$RYTM $VKTX I’m not overlooking it, I just understand the science better than you. VK2735 is better because it is a peptide. Oral wegovy is also peptide and outselling Foundayo threefold this year (because total weight loss is greater). Peptides seem to be more effective for total weight loss. Not eating or drinking for 30 minutes is absolutely trivial and not in any way a major deterrent unless you are an absolute bitch 🤷‍♂️. VK oral is not subpar - phase 2 data was exploratory with a fast titration. Despite the side effects in the first few weeks, after week 3 all of the arms including high dose saw less than 5% vomiting at any other week in the trial. 30mg cohort was close to placebo despite titration.
2 replies
Freakyguy666 Oct 5, 12:54 AM
$RYTM $VKTX you’re overlooking the fact that vk2735 is not a small molecule and therefore will require taking the pill with NO FOOD & NO WATER FOR AT LEAST 30 MINUTES…. This is not only extremely inconvenience compared to the competing orals with no such restrictions—it also results in MORE NAUSEA. I like vk2735 as a SubQ but Oral is SUB PAR…And the big Acquirers are reluctant to invest in a 2nd Tier product especially when the CEO wants TOP TIER Money.
1 replies